Rational site-directed pharmacotherapy for major depressive disorder

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Major Depressive Disorder (MDD) is increasingly recognized as a heterogeneous condition, not a single pathophysiological entity.
• This complexity contributes to low remission rates observed with first-line antidepressant monotherapy.

Purpose of the Study:

• To explore the rationale behind low antidepressant remission rates.
• To discuss alternative and adjunctive pharmacological targets for MDD treatment, particularly in treatment-resistant cases.

Main Methods:

• Review of current understanding of MDD pathophysiology.
• Analysis of various monoaminergic targets and their modulation by gene polymorphisms.
• Examination of the pharmacological profiles of antidepressants and atypical antipsychotics.

Main Results:

• Antidepressants acting on single targets like serotonin transporters show efficacy, but other targets are crucial for treatment resistance.
• Additional targets include norepinephrine transporters, monoamine oxidase, specific serotonin receptors (5-HT2A, 5-HT1B, 5-HT7), and dopamine 2 receptors.
• Atypical antipsychotics share some targets but require careful dosing to avoid counter-productive dopamine 2 antagonism in MDD.

Conclusions:

• The multifaceted nature of MDD necessitates a broader therapeutic approach beyond single-target antidepressants.
• Combination therapies or agents with multiple targets, including atypical antipsychotics at sub-psychotic doses, may offer benefits for treatment-resistant depression.
• Individualized treatment strategies considering genetic polymorphisms and multiple neuronal targets are essential for optimizing MDD management.